Serge Saxonov - Jun 8, 2021 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role
Chief Executive Officer, Director
Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact
Stock symbol
TXG
Transactions as of
Jun 8, 2021
Transactions value $
-$2,656,934
Form type
4
Date filed
6/10/2021, 04:25 PM
Previous filing
May 26, 2021
Next filing
Jul 8, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Gift $0 -200 -0.02% $0.00 904K Jun 4, 2021 Direct
transaction TXG Class A Common Stock Options Exercise $26.3K +5.21K +0.58% $5.04* 909K Jun 8, 2021 Direct F1
transaction TXG Class A Common Stock Options Exercise $112K +9.79K +1.08% $11.48* 919K Jun 8, 2021 Direct F1
transaction TXG Class A Common Stock Sale -$111K -600 -0.07% $184.17 918K Jun 8, 2021 Direct F1, F2
transaction TXG Class A Common Stock Sale -$407K -2.2K -0.24% $185.05 916K Jun 8, 2021 Direct F1, F3
transaction TXG Class A Common Stock Sale -$855K -4.6K -0.5% $185.89 912K Jun 8, 2021 Direct F1, F4
transaction TXG Class A Common Stock Sale -$979K -5.24K -0.57% $186.91 906K Jun 8, 2021 Direct F1, F5
transaction TXG Class A Common Stock Sale -$444K -2.36K -0.26% $187.92 904K Jun 8, 2021 Direct F1, F6
holding TXG Class A Common Stock 90K Jun 8, 2021 See Footnote F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (right to buy) Options Exercise $0 -5.21K -5.8% $0.00 84.6K Jun 8, 2021 Class A Common Stock 5.21K $5.04 Direct F1, F8
transaction TXG Stock Option (right to buy) Options Exercise $0 -9.79K -10.06% $0.00 87.5K Jun 8, 2021 Class A Common Stock 9.79K $11.48 Direct F1, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
F2 This transaction was executed in multiple trades at prices ranging from $183.43 to $184.42. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $184.45 to $185.43. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $185.45 to $186.40. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 This transaction was executed in multiple trades at prices ranging from $186.465 to $187.46. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6 This transaction was executed in multiple trades at prices ranging from $187.49 to $188.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7 The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F8 This option, originally for 250,000 shares, of which 165,427 have been exercised, vested as to one forty-eighth of the shares on October 1, 2018, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F9 This option, originally for 145,786 shares, of which 58,281 have been exercised, vested as to one forty-eighth of the shares on May 1, 2019, and one-forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.